Wolfgang Miesbach/LinkedIn
Feb 25, 2026, 12:36
Wolfgang Miesbach: Repurposing Metformin – From Sugar Control to Thrombus Control
Wolfgang Miesbach, Professor of Medicine at Frankfurt University Hospital, shared on LinkedIn:
”Repurposing Metformin: From Sugar Control to Thrombus Control
One of the many excellent posters at this year’s GTH 2026 meeting in Bonn was from the team in Düsseldorf, exploring an unexpected player in abdominal aortic aneurysm (AAA) therapy: the antidiabetic drug metformin.
Their work looks at how metformin modulates platelet activation and ex vivo thrombus formation in human whole blood – a fascinating angle, given the growing recognition that platelets and intraluminal thrombus are not just bystanders but active drivers of AAA progression:
- A ‘classic’ diabetes drug being repurposed to target vascular inflammation and thrombosis, in a disease area where truly effective pharmacological treatments are still lacking.
- Experimental data suggesting that metformin can inhibit platelet activation and arterial/venous thrombosis without prolonging bleeding time, by acting on mitochondrial pathways – hinting at a new, ‘metabolic’ form of antiplatelet therapy.
- Use of human samples and arterial‑shear thrombus assays keeps the model close to clinical reality and directly links cellular mechanisms to the thrombotic milieu observed in AAA.
- The concept that dampening platelet hyperreactivity might not only reduce thrombotic complications but also slow aneurysm expansion is particularly attractive and could complement ongoing clinical trials of metformin in AAA.”
Stay updated with Hemostasis Today.
-
Apr 14, 2026, 17:32Denise M.: Surviving Sepsis 2026 – The Upstream Revolution
-
Apr 14, 2026, 17:23Meghanath Yenni։ What’s New in Acute Ischemic Stroke in 2026
-
Apr 14, 2026, 17:11Phil Spinella: What Dose of TXA for Children With Severe Traumatic Bleeding Should You Use?
-
Apr 14, 2026, 17:08Abdulrahman Katib: How Endovascular Stenting Is Transforming the Treatment of Severe PTS
-
Apr 14, 2026, 17:00Anna A. Avagyan: Glad to Be Part of EHA Pediatric Hematology-Oncology Course
-
Apr 14, 2026, 16:58Ney Carter Borges: NLRP3 Inhibition in Atherosclerosis – Early Clinical Signal Beyond Lipids
-
Apr 14, 2026, 16:56Saskia Middeldorp: Key Takeaways from the 2026 ACC/AHA Guideline on Acute PE
-
Apr 14, 2026, 16:54Chokri Ben Lamine: Extracorporeal Photopheresis for aGVHD cGVHD Post-SCT – 50 Pearls
-
Apr 14, 2026, 16:49Ahmed Magdi Omar: Key Takeaways From the Latest 2026 Guidelines on Antiplatelet Therapy in AIS